Has tumor doubling time in breast cancer changed over the past 80 years? A systematic review.
breast cancer
molecular subtypes
screening
tumor doubling time
tumor growth rate
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
revised:
03
04
2021
received:
23
01
2021
accepted:
12
04
2021
pubmed:
16
7
2021
medline:
15
2
2022
entrez:
15
7
2021
Statut:
ppublish
Résumé
Over the past century, epidemiologic changes and implementation of screening may have had an impact on tumor doubling time in breast cancer. Our study was designed to evaluate changes in tumor doubling time in breast cancer over the past 80 years. A systematic review of published literature and meta-regression analysis was performed. An online electronic database search was undertaken using the PubMed platform from inception until June 2020. All studies that measured tumor doubling time in breast cancer were included. A total of 151 publications were retrieved. Among them, 16 full-text articles were included in the qualitative analysis. An exponential growth model was used for quantitative characterization of tumor growth rate. Tumor doubling time has remained stable over the past 80 years. Recent studies have not only identified "fast growing tumor" (grade 3, human epidermal growth factor receptor 2-positive, triple-negative, or tumor with an elevated Ki-67) but also "inactive breast cancer" feeding the ongoing debate of overdiagnosis due to screening programs. The stability of tumor doubling time over the past 80 years, despite increasing and changing risk factors, supports the validity for our screening guidelines. Prospective studies based on more precise measurement of tumor size and adjustment for tumor characteristics are necessary to more clearly characterize the prognostic and predictive impact of tumor doubling time in breast cancer.
Identifiants
pubmed: 34264009
doi: 10.1002/cam4.3939
pmc: PMC8335823
doi:
Substances chimiques
Ki-67 Antigen
0
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
5203-5217Subventions
Organisme : Malakoff Mederic group
Informations de copyright
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Eur J Radiol. 2013 Sep;82(9):1416-22
pubmed: 23567481
Cancer Res. 1988 Dec 15;48(24 Pt 1):7067-71
pubmed: 3191483
Cancer. 1980 Apr 15;45(8):2198-2207
pubmed: 7370960
Jpn J Cancer Res. 1990 May;81(5):454-62
pubmed: 2116393
Cancer. 1968 Mar;21(3):461-7
pubmed: 4295433
Cancer. 1977 Oct;40(4):1722-5
pubmed: 907980
Ann Surg. 2011 Apr;253(4):779-85
pubmed: 21475020
Cancer Res. 2007 Apr 15;67(8):3970-5
pubmed: 17440113
AJR Am J Roentgenol. 1997 Aug;169(2):417-24
pubmed: 9242745
Chest. 1981 May;79(5):612-3
pubmed: 7226945
Qual Health Res. 2002 Nov;12(9):1284-99
pubmed: 12448672
JAMA. 2018 Jan 23;319(4):388-396
pubmed: 29362800
Adv Exp Med Biol. 2019;1152:9-29
pubmed: 31456177
Eur J Radiol. 2003 Dec;48(3):285-92
pubmed: 14652148
Med Sci Monit. 2017 Jun 27;23:3147-3153
pubmed: 28652562
J Clin Oncol. 2012 Dec 20;30(36):4485-92
pubmed: 23169513
PLoS One. 2015 Dec 10;10(12):e0144144
pubmed: 26657267
Medicine (Baltimore). 2016 Sep;95(37):e4874
pubmed: 27631256
Cancer. 1979 May;43(5):1888-94
pubmed: 445375
Cancer. 1972 Aug;30(2):594-9
pubmed: 5051683
Br J Cancer. 1985 Oct;52(4):515-24
pubmed: 4063132
Radiat Prot Dosimetry. 2016 Jun;169(1-4):151-7
pubmed: 26410768
Cancer. 1989 Nov 15;64(10):2081-9
pubmed: 2804897
Cancer. 1993 Jun 1;71(11):3547-51
pubmed: 8490903
Eur J Cancer. 2005 Jul;41(11):1610-7
pubmed: 15978801
Eur Radiol. 2014 Sep;24(9):2227-35
pubmed: 24895040
Cancer Med. 2021 Aug;10(15):5203-5217
pubmed: 34264009
Natl Cancer Inst Monogr. 1969 May;30:15-28
pubmed: 5351826
Br J Cancer. 1986 Nov;54(5):833-6
pubmed: 3801276
Breast Cancer. 2019 Mar;26(2):206-214
pubmed: 30259332
J Surg Oncol. 1997 Aug;65(4):284-97
pubmed: 9274795
Science. 2020 May 8;368(6491):589-590
pubmed: 32381710
Cancer. 1963 Aug;16:961-4
pubmed: 14050014
Radiol Med. 2013 Oct;118(7):1119-36
pubmed: 23801389
Lancet. 2012 Nov 17;380(9855):1778-86
pubmed: 23117178